GLP-1 Drugs Linked to Lower Cancer Progression Across Multiple Tumor Types — Cleveland Clinic Study at ASCO 2026

A groundbreaking retrospective cohort study led by researchers at the Cleveland Clinic's Taussig Cancer Institute has revealed that GLP-1 receptor agonists (GLP-1RAs) are associated with a substantial 31% to 50% reduction in the risk of metastatic progression to stage IV disease across four major obesity-related solid tumor types compared to other antidiabetic medications.

The study, which will be formally presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 3510), evaluated real-world health records from the TriNetX Global Health Research Network. Researchers analyzed a propensity-matched cohort of 12,112 patients (6,056 matched pairs) with stage I to III obesity-related cancers who initiated either a GLP-1RA or a DPP-4 inhibitor (gliptin) after their cancer diagnosis.

The analysis demonstrated highly statistically significant reductions in metastatic progression for four solid tumor types:

• Non-Small Cell Lung Cancer (NSCLC; 2,157 pairs): A 50% risk reduction (HR, 0.50; 95% CI, 0.43-0.59; P < .001), with a cumulative incidence of stage IV progression of 10.0% in the GLP-1RA group versus 22.3% in the gliptin group.
• Breast Adenocarcinoma (1,187 pairs): A 43% risk reduction (HR, 0.57; 95% CI, 0.46-0.71; P < .001), with a cumulative incidence of 10.2% versus 20.1%.
• Colorectal Adenocarcinoma (784 pairs): A 31% risk reduction (HR, 0.69; 95% CI, 0.54-0.88; P = .003), with a cumulative incidence of 13.4% versus 22.2%.
• Hepatocellular Carcinoma (HCC; 275 pairs): A 38% risk reduction (HR, 0.62; 95% CI, 0.44-0.89; P = .009), with a cumulative incidence of 18.9% versus 28.4%.

While the differences in three other cancer types (prostate, renal cell, and pancreatic) favored GLP-1RAs, they did not reach statistical significance, potentially due to smaller sample sizes or tumor-dependent biological profiles.

Mechanistic Evidence Beyond Weight Loss

To investigate the biological mechanism behind these findings, the investigators performed a secondary analysis using genomic data from The Cancer Genome Atlas (TCGA). They discovered that high intratumoral expression of the GLP-1 receptor (GLP-1R) was associated with a 33% lower risk of overall mortality across the seven cancer types compared to low expression. This effect was most pronounced in breast cancer, where high expression correlated with a 45% reduction in mortality risk.

This genomic correlation strongly suggests that the oncology benefits of GLP-1RAs are driven by direct, tumor-level biological signaling rather than being merely a downstream byproduct of weight loss or glycemic control. Additionally, the study reported no elevated rates of pancreatitis or gastric inflammation in the GLP-1RA cohort compared to the gliptin cohort, easing historical concerns about gastrointestinal toxicities in oncology patients.

Verbatim Quotes and Interpretation

"Our study found that use of GLP-1 drugs, compared to DPP-4 inhibitors and other antidiabetic drugs, was associated with a meaningful reduction in cancer progression across 4 solid tumor types. It provides early evidence that future studies are worth pursuing," said lead study author Mark David Orland, MD, of the Taussig Cancer Institute at Cleveland Clinic.

"GLP-1 receptor agonists have never been just glucose-lowering drugs. Their anti-inflammatory and immune-modulatory properties have long suggested broader effects. What's new here is the consistency across tumor types, and data this large and this consistent warrant a prospective randomized trial," stated Marcin Chwistek, MD, FAAHPM, Chief of Supportive Oncology and Palliative Care Program at Fox Chase Cancer Center and an ASCO Expert.

For healthcare investors, these findings represent an enormous potential expansion of the total addressable market (TAM) for GLP-1 drugs. If prospective randomized trials confirm these observational findings, GLP-1 receptor agonists could become a standard adjuvant or supportive therapy in oncology, fundamentally altering the treatment paradigm for patients diagnosed with early-stage obesity-related solid tumors.